EATRIS is pleased to announce that Anton Ussi’s mandate as Operations & Finance Director has been renewed for a third term, running from 2025 to 2030. The unanimous decision was made during the Board of Governors Meeting held in Madrid, Spain, on 4 December 2024.
The Board expressed its gratitude for Anton’s leadership and dedication during his first two terms, highlighting his role in advancing EATRIS’s mission to enhance the translational medicine ecosystem for the benefit of patients.
Reflecting on his third term, Anton commented: “It is both a privilege and a joy to continue working in this important area with such an extraordinary team. As we enter our second decade of operations, we have the opportunity to truly leverage the power of the trans-disciplinary community we’ve assembled, scaling out our successful operational areas and zeroing in on the high-need areas, such as advanced therapies and artificial intelligence in healthcare.”
Jelena Ilić-Dreven, Chair of the EATRIS Board of Governors, shared her thoughts on the renewal: “We are delighted to confirm Anton Ussi as Operations & Finance Director for a further five years. Since 2015, Anton has provided exemplary leadership, and the Member States look forward to collaborating with him as EATRIS continues to drive the translation of biomedical discoveries into real-world patient benefits.“
Toni Andreu, EATRIS Scientific Director, added: “It has been remarkable to witness the progress made under Anton’s leadership. While we’ve achieved significant milestones, much remains to be done to advance biomedical innovation and human health in Europe. Anton’s vision and expertise are exactly what we need to accomplish our ambitious goals.“
Anton’s leadership journey with EATRIS began in 2015, and during his tenure, EATRIS membership has doubled, the number of users annually has increased by almost ten-fold, and the services and project portfolio has grown significantly. His continued stewardship promises to further strengthen EATRIS’s impact in the years ahead.
